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Drug treatment of functional dyspepsia is often unsatisfactory. We assessed the efficacy of a
bicarbonate-sulphate-calcium thermal water cycle of 12 days, in patients with functional dyspepsia.
Patients with functional dyspepsia were sent by their general practitioners to 12 days of treatment with
thermal water, 200–400 ml in the morning, at temperature of 33 C (91.4 F) and were evaluated on a strict
intention to treat basis. Four efficacy endpoints were analyzed as follows: (i) reduction of the global
symptoms score, (ii) reduction of intensity to a level not interfering with everyday activities, (iii) specific
efficacy on ulcer-like or dysmotility-like dyspepsia and (iv) esophageal or abdominal-associated
symptoms. Statistical significance was reached for all three primary outcomes after the first 29
consecutive patients. Thermal water reduced the global symptom score, reduced intensity of symptoms
to a level not interfering with everyday activity, but was unable to completely suppress all symptoms. A
parallel effect emerged for ulcer-like and dyspepsia-like subgroups. The effect on heartburn and
abdominal symptoms was not significant, suggesting a specific effect of the water on the gastric and
duodenal wall. The Roma II criteria identify a natural kind of dyspepsia that improves with thermal
water. Ulcer-like and dysmotility-like are not therapeutically distinguishable subgroups. Patients with
dominant esophageal or abdominal symptoms should receive a different therapy. Sequential methods are
very effective for the evaluation of traditional care practices and should be considered preliminary and
integrative to randomized controlled trials in this context.
Keywords: balneotherapy – functional dyspepsia – functional gastrointestinal
disorders – hydrotherapy – sequential methods – spa – thermal care
Introduction
Science, broadly defined, is also the knowledge obtained by
study of traditional practices after a careful trial showing the
predictability of their effects in identifiable groups of patients.
Today, when functional dyspepsia is diagnosed, the drug
treatment is often unsatisfactory (1), many patients are advised
to drink different waters and types of wine, to change their diet
(2) and introduce vitamins or are referred to a spa without
much effort to individualized care (3–5). Without clear
descriptions of patient symptoms and syndromes, it is difficult
for the primary physicians to lump together typical groups of
patients in order to test their response to specific treatments
and transform a traditional art in explicit and public scientific
knowledge (6–8).
In the past three decades, following the example of
psychiatrists and rheumatologists, symptom-based diagnostic
criteria for functional gastrointestinal disorders have been
suggested (9–11). When they allow the identification of
natural groups of patients responsive to a specific kind of
treatment (12), they are extremely useful in the daily medical
practice, considering that functional gastrointestinal disorders
For reprints and all correspondence: Giuseppe Rocca, Direzione Scientifica,
Fondazione Policlinico Milano, Italy. Tel: þ39-333-2693227; Fax: þ39-2-
5503-8331; E-mail: bepperocca@policlinico.mi.it
  2006 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.representalargeproportion—morethan50%—ofgastroentero-
logists’ referral, at least in the rich countries (13,14).
Since one in every four persons in these societies has
symptoms compatible with one of the component functional
diagnoses, these syndromes have been known for centuries,
albeit with variable expressions of the primary symptoms.
Rich Etruscans and Romans spent all day at the Terme and the
Chianciano water is known for its gastroduodenal healing
effects since then.
Why have we accrued so little knowledge of the specific
type of patients that can take advantage and relief from this
traditional style of treatment? There are both historical and
scientific explanations: for centuries to spend days or months
at the Terme was a luxury for few privileged riches, a sign of
social distinction and a status symbol. After the Second World
War, in both West and East Europe, thermal care was
reimbursed by the Welfare State, but was considered a kind
of non-specific panacea against any kind of undefined stress,
or as a benefit for tired workers and exhausted housewives. No
clear definition of functional bowel diseases existed, nor was
there any recognition that patients should be selected in order
to benefit from this traditional kind of therapy (15–18).
As a result, thermal care turned out to be considered non-
scientific and its popularity declined with the economical
restrictions of the eighties. Today spas are coming back with a
revenge—they sono di moda—partly because a growing
number of patients affected by functional disorders is
dissatisfied with the few available drugs (19,20).
Methods
Study Design and Patient Population
A group of general practitioners of the Tuscany Region was
trained in the use of the Rome II—and a preliminary draft of
the Roma III criteria (21)—for dyspepsia and other functional
gastrointestinal disorders, in Continuing Medical Education
courses (Educazione Continua in Medicina, ECM) focused on
the classification of clinical cases (22).
Patients considered to have functional dyspepsia on the basis
of the Rome II criteria were eligible for the trial. Functional
dyspepsia was diagnosed if persistent or recurrent upper
abdominal pain or discomfort was the dominant complaint
(23). Pain consisted of epigastric pain or burning; discomfort
was characterized by the presence of one or more symptoms
that included postprandial fullness, early satiety, gastric
distension, belching, nausea or vomiting. Symptoms had to
be present for at least 12 weeks within the previous 12 months.
Since it is well known that many patients have clinical
pictures characterized by the overlap of different functional
disorders, to increase the specificity and precision of the trial,
only patients with predominant functional dyspepsia were
included in the study.
Esophageal reflux disorder, other functional esophageal
disorders, irritable bowel syndrome and functional abdominal
pain identified by the application of the Rome II criteria were
excluded when presenting as the predominant problem.
Biliary disorders, Helicobacter pilori infection (24), struc-
tural lesions or clinically significant biochemical abnor-
malities were excluded by recent available documentation or
ad hoc ecotomography, blood tests including fasting blood
sugar and liver function tests and gastrointestinal endoscopy
(25,26).
Patients were excluded if they were already taking other
medications that may alter gastric function on a regular basis
and if they were known by the general practitioners as heavy
drinkers, heavy smokers or habitual drinkers of more than 2–3
cups of coffee every day (27).
From a methodological perspective, traditional clinical trials
are too expensive and difficult to apply to thermal care. In
controlled clinical trials for the comparison of two drugs and
for registration, the number of observation is decided in
advance and is not affected by the observed results of
treatment after each patient has completed therapy. Very
often, when assessing a traditional practice of care, the
efficacy is unpredictable before its start but depends on the
observed results in a series of individual patients. The decision
to stop the investigation depends on the results. A study of this
type is called sequential (28), following Wald (29), Armitage
(30) and Whitehead (31). The main reason for using sequential
methods are as follows: (i) economy emerging from the
possibility to reduce the total amount of experimentation
depending on the efficacy of the treatment under study and the
results obtained in the patients already completed, (ii) the
possibility to achieve a specified 0.05 sensitivity and 80%
power of the study without being forced to anticipate a
numerical estimate of treatment effect, (iii) ethical considera-
tions preclude random allocation or the use of placebo when
there is strong historical and anecdotal prior evidence—or
common belief—in the efficacy of a traditional form of
treatment and (iv) for the same reason it would be undesirable
to continue following the tradition when the treatment is
shown by sequential medical trials to be no better than the
tossing of a balanced coin.
The ethical committee approved the research and each
patient knew of his involvement in a study protocol and signed
a written informed consent of agreement to using resulting
information for medical publications; no candidate patient
refused the prescription of 12 days in Chianciano or to
participate in the study.
Characteristics of the Thermal Water
The protocol consisted of 200–400 ml of thermal water every
morning, before breakfast, for 12 days. The thermal source has
a constant temperature of 33 C (91.4 F) and in this form is
assumed by the patients going to Chianciano.
It is also available in glass bottles but in this case it is not
classified as thermal water, but as a bicarbonate-sulphate-
calcium mineral water, is usually drunk at ambient tempera-
ture, and in our experience does not have the same therapeutic
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population involved in this research. The chemical composi-
tion of the water is reported in Table 1.
Assessments
A standardized questionnaire based on the Leeds Dyspepsia
Questionnaire (32) and already tested for validity by our group
in a previous study of mineral water (33) was filled by each
patient before going to Chianciano and in the first week after
the end of treatment.
For clarity symptoms were divided into (i) specific of
functional dyspepsia and (ii) associated. The specific were
epigastric pain, epigastric burning, postprandial fullness, early
satiety, gastric distension, nausea and vomiting. Heartburn,
regurgitation, functional dysphagia, chest pain, abdominal
pain and abdominal distension, were considered as associated
and in no case they dominated the clinical picture of the
individual patient.
For each symptom frequency was rated on a 4 levels ordinal
scale as follows: (i) occasional or regular but no more than
1 day for week, (ii) presenting 2–3 days every week, (iii) 4–6
days a week and (iv) almost continuous. The intensity was
rated as follows: (i) no modification of everyday activity,
(ii) interfering with everyday activities, (iii) induced modi-
fication of everyday activities and (iv) forced in bed when
symptoms were present.
Statistical Analysis
Sequential Trial with Closed Plan
A sequential trial was the statistical model applied in the
design and analysis of the study. The sensitivity chosen for the
boundary conditions was a ¼ 0.05 and the power q ¼ 0.80. To
avoid the possibility of exceptionally large sample sizes while
preserving the required statistical characteristics of the study,
the plan was truncated at 38 patients by applying the upper,
lower and middle boundaries of a Restricted Sequential Plan
(RSP) by Armitage (30).
As we know that 40–45% of patients may improve simply
because of a placebo effect or as a regression to the mean
phenomenon, in order to avoid the need for a control group, the
comparison was done assuming a fixed standard (30) much
higher than the conventional null hypothesis. In fact we
required the efficacy to be predictable in 80% of patients in
fixing the boundaries of the sequential trial instead of 50%.
To test the inefficacy of water on heartburn and abdominal
syndrome, an open sequential trial with the same power and
requirements was applied, as Armitage showed this design to
be more efficient to prove that the null hypothesis is in fact
true (30). Following the sequential trial terminology, each
patient at the end of the trial can be classified as follows: (i) a
success, (ii) a failure and (iii) unchanged or not responsive to
this treatment. Only successes and failures are considered
preferences and are included in the statistical analysis, but for
the clinician the number unchanged is also of great relevance.
Many different successful criteria of the trial were tested as
follows: (i) a reduction of the global score for both specific and
accessory symptoms of at least 3 points (clinically significant),
(ii) a reduction of the global score for symptoms specific of
functional dyspepsia of at least 3 points and (iii) the presence
of no symptoms with an intensity greater then 2 (no com-
promise in everyday activity) or greater than 1 (complete
resolution). All other outcomes were counted as no change or
insufficient change and cumulated as failures for the statistical
analysis.
Epigastricpainandepigastricburningwere groupedtogether
as ulcer-like syndrome. Postprandial fullness, early satiety,
gastric distension, nausea and vomiting were considered part
of the dysmotility-like syndrome. The reduction in both the
ulcer-like and the dysmotility-like syndrome was tested with
the criteria of at least 3 points reduction of intensity.
Although accessory in the clinical picture of patients, both
heartburn and abdominal distension and pain were analyzed
separately for the reduction of intensity of at least 3 points.
Results
Study Population
The characteristics of each individual patient and the
frequency and intensity of each symptom before (B) and after
(A) treatment are reported for specific symptoms in Table 2
and for accessory symptoms in Table 3. Since the trial focused
on individual patients, no use has been done of averages or
other summary statistics calculated on the whole group (the
availability of complete raw data make it easy to do it if the
reader consider it more informative).
Response to Treatment
Figure 1 shows the results of the sequential trial when a
reduction of the global score for all symptoms (specific plus
accessory) of at least 3 points (clinically relevant) as the effect
of treatment is considered. The horizontal axis shows the
Table 1. Chemical characteristic of the Chianciano thermal water
Ion g l
 1
SO4
2 1 1.8400
HCO
3 1 0.7300
Ca
2þ 0.8400
Mg
2þ 0.1800
Na
þ 0.0410
Cl
 1 0.0294
Sr
2þ 0.0001
K
þ 0.0070
F
 1 0.0020
Fe
2þ 0.0008
Br
2þ 0.0002
Free CO2 537 ml l
 1
eCAM 2007;4(3) 383Table 2. Specific symptoms
B: before treatment; A: after treatment; Freq: frequency score; Int: intensity score
384 Thermal care of functional dyspepsia: sequential trialTable 3. Accessory symptoms
Legend B: before treatment; A: after treatment; Freq: frequency score; Int: intensity score
eCAM 2007;4(3) 385number of patients; the vertical axis the excess preferences or
successes. The continuous thick lines are the upper, lower and
middle boundaries typical of a sequential plan for the required
sensitivity and power of the trial. The efficacy of treatment on
each patient of the series is analyzed sequentially. As soon as
the effect on a new patient is known, the line move up one unit
if the case is a success, move down one unit if it is a failure.
When the series of data crosses the upper boundary the
treatment is a statistically significant success, when it crosses
the lower boundary is a statistically significant failure. If the
series crosses the median boundaries the treatment is not
effective in more than 80% of patients (null hypothesis). In our
case, after the first 20 preferences the upper boundary was
crossed and the efficacy of water in more than 80% of patients
was confirmed.
Figure 2 shows results for score based on symptoms specific
for functional dyspepsia. A definitive significance was reached
after 23 preferences.
Figure 3 shows the number of patients with no impairment
of everyday activities as a result of treatment (symptoms with
an intensity lower or equal 2), or asymptomatic—intensity
 1—after treatment. A vast majority of patients benefited
from an improvement of symptoms to the range of intensity
not interfering with activities of daily living and statistical
significance was obtained after nine preferences. On the
contrary complete suppression of symptoms is not a realistic
outcome of treatment and the series shows no statistical
significance after 27 preferences.
Figure 4 shows the effect of water on the ulcer-like
syndrome with a clinical success defined as a reduction of
intensity of at least 3 points of symptoms as before. After 15
preferences the significance was reached. Figure 5 shows the
effect on the dysmotility-like syndrome using the same
criteria. The significance was reached after 17 preferences.
For the associated symptoms, Fig. 6 shows the non-significant
effect of the water on heartburn and the abdominal syndrome.
The sequential analysis is somewhat different from the
previous ones because we wanted the middle boundaries to
be very sensitive to the negative results suggested by previous
experience (30).
Discussion
The Chianciano thermal water care is an effective short-term
therapy for the specific and associated symptoms of functional
dyspepsia in a carefully selected group of patients. Parallel
results are obtained when only the specific symptoms are
analyzed (Figs 1 and 2). For practicing physicians the most
relevant result is the very small number of individual patients
showing no improvement and the significant number benefit-
ing from a marked clinical improvement. This is confirmed by
the statistically significant number of patients in whom we saw
a change with the disappearance of impairment in everyday
activities because of symptoms intensity (Fig. 3). Vice versa,
the complete disappearance of symptoms is not what physi-
cians should promise to patients, as shown by the non-
significant series in Fig. 3 where no symptoms with an
intensity  1 was the required outcome.
If the pattern of response to a specific therapy is accepted as
evidence of the underlying disease mechanism and classifica-
tion validity, thermal care emerges from the trial as a specific
treatment for functional dyspepsia and associated symptoms,
but does not confirm the possibility to differentiate between
ulcer-like and dysmotility-like subgroups. On the contrary, the
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Figure 1. Global score for all symptoms including specific and accessory symptoms.
386 Thermal care of functional dyspepsia: sequential trialmarked parallelism among the series of patients for the two
syndromes suggests that as far as therapy is involved, they
should be classified together (Figs 4 and 5) (34,35).
Thermal water and care has no significant effects on
heartburn and the abdominal syndrome (Fig. 6), suggesting a
specific effect of therapy at the gastroduodenal level and the
possibility of different mechanisms for therapies targeted at
the esophageal and abdominal walls (36–39).
The trial confirms the validity and practical utility of the
Roma II criteria for identification of patients affected by
functional dyspepsia and its inclusion among the gastroduo-
denal disorders, but does not confirm the more specific
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Figure 2. Specific score for functional dyspepsia.
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Figure 3. Intensity of symptoms interfering with everyday activity.
eCAM 2007;4(3) 387subgroups of ulcer-like and dysmotility-like dyspepsia as a
criterion that makes a difference for treatment (40–42). Both
functional esophageal disorders and abdominal disorders need
a different and more specific type of therapy (43–46).
The study confirms the great practicality of the sequential
trial approach to test the efficacy of traditional kinds of care on
individual patients. If treatment is very efficacious, as in this
case, a small number of carefully selected patients are
sufficient to test the many hypotheses emerging from
traditional wisdom or previous experience while avoiding the
ethical, practical and economic difficulties of applying the
more standard fixed-number trial approach.
The major weak point of the sequential approach is that the
evidence for efficacy is often reached with very few patients;
as expected, the confidence limits for the percentage of success
obtained are wide. This is not critical when the efficacy of the
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Figure 4. Ulcer-like syndrome.
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
2
4
6
8
10
12
14
16
18
0 5 10 15 20 25 30 35 40
Number of preferences
Upper Boundary
Lower Boundary
Middle Boundary
Middle Boundary
Figure 5. Dysmotility-like syndrome.
388 Thermal care of functional dyspepsia: sequential trialtreatment is great, but limit their application to the comparison
of drugs or remedies when a small difference is expected (for
example in the comparison of two statins or proton pump
inhibitors).
As far as the practical physician is concerned, the sequential
approach gives information at the individual level, avoiding
the abstract presentation of table of averages and percentages
without any precise indication of the concrete type of person
that can take advantage of the tested practice of care. For this
reason, the complete database of individual data is provided as
part of the results and no summary measure has been
calculated. The concrete individualized approach should help
the physician in the application of the results to the precisely
described natural kind of patient they can encounter in
everyday ambulatory practice (47).
Nobody can believe that 12 days of care, although very
effective, can have positive effects lasting forever on
functional gastrointestinal disorders that we know for their
chronic course. The next studies should answer the many
questions that the positive results reported make urgent: how
long the positive effects of 12 days in Chianciano last? How
often should the cycle be repeated in order to optimize the
improvements? Is the practice best for prevention in mildly
affected patients, or is it better to prescribe it when the clinical
pattern is more severe, as in these patients? Does the
availability of a regular and individualized schedule in each
case improve the quality of life and reduce the direct and
indirect costs of functional dyspepsia? Do these patients need
the association of other kinds of treatment or is thermal care
enough by itself for the long-term care of functional
dyspepsia? Why thermal care is more effective than the
equivalent mineral water based care? Is any extramolecular
mechanism involved? (48)
We believe that this study is only the first step toward a more
scientific approach to the evaluation of many types of tradi-
tional care now di moda and reimbursed by both the welfare
state and insurance companies in many countries.
The emerging specificity of thermal care for a easily
identified group of patients, affected by a specific functional
disorder confirm our assumption that many kinds of traditional
care are not panacea or placebos, but show specific activity at
precise levels or organs of the body and on specific and
recognizable symptoms, patterns and syndromes.
The results of the study suggest that it is important to test the
efficacy of different practices of thermal and other traditional
care on different disorders, upon different levels of the
gastrointestinal tract and on different organs and systems of
the body. This can be done easily and scientifically by the
application of the sequential trial approach. Stimulated by the
results of this study, a randomized controlled trials (RCT) is
under way to compare the efficacy, direct and indirect costs,
and duration of the positive effect of thermal water compared
to standard treatments.
Why in our experience does thermal water and mineral
water, with the same chemical composition give different
results in the same group of patients? The available literature
and the regulation for reimbursement are focused mainly or
exclusively on the molecular effect of the minerals—chemical
analysis—while in our experience other three factors should
be integrated in future research as follows: (i) the temperature
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eCAM 2007;4(3) 389at the moment of ingestion, (ii) a possible homeopathic effect
of thermal water but not mineral water due to the passage on
diluted minerals and (iii) the relaxing effect of 12 days at a
spa, that is missing when the patients drinks the mineral water
at home. No data at the moment are available to estimate the
integrated contribution of each of these three additional
factors.
The traditional classification of therapeutic waters is based
on the chemical characteristics, but experience with patients
suggests that other factors should be taken into account in
future research. The Rome II and Rome III definition of
functional dyspepsia consider these symptoms as specific of
the syndrome. Most patients affected by functional dyspepsia
are affected also by other symptoms that do not dominate the
clinical picture but are accessory and often present.
Thermal care is effective in reducing the global score for all
symptoms in more than 80% of patients after only 20 trials. It
targets the specific symptoms for functional dyspepsia and is
effective in 80% of patients after only 23 trials. Thermal care is
effective in reducing symptoms to a level not interfering with
everyday activities—significant after nine patients—but is
generally unable to completely suppress the symptoms—non-
significance after 27 trials.
Rome II criteria defines ulcer-like syndrome as a subgroup
of functional dyspepsia, but Figs 4 and 5 show that they are not
therapeutically distinguishable. The results are similar to those
obtained with patients affected by ulcer-like dyspepsia,
suggesting they are not therapeutically distinguishable. The
Chianciano thermal care is ineffective against esophageal and
abdominal symptoms, showing a specific effect on the wall of
the stomach and duodenum.
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